Evidence map›Paper›PMID 35626701›Full record

ArticleCells2022

Restoration of BDNF, DARPP32, and D2R Expression Following Intravenous Infusion of Human Immature Dental Pulp Stem Cells in Huntington's Disease 3-NP Rat Model.

Cristiane Valverde Wenceslau, Dener Madeiro de Souza, Nicole Caroline Mambelli-Lisboa, Leandro Hideki Ynoue, Rodrigo Pinheiro Araldi, Joyce Macedo da Silva, Eduardo Pagani, Monica Santoro Haddad, Irina Kerkis

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06097780 (Phase III Efficacy and Safety of NestaCell® in Moderated Huntington's Disease), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06097780 phase3unknown statusnot on this mapstarted 2024, after this paper: background citation

Phase III Efficacy and Safety of NestaCell® in Moderated Huntington's Disease

TypeinterventionalSponsorAzidus BrasilRan2024 to 2026Enrolled120ConditionsHuntington DiseaseArmsNestaCell®
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Cristiane Valverde WenceslauCellavita Pesquisas Científicas Ltda., Valinhos 13271-650, SP, Brazil.
Dener Madeiro de SouzaGenetics Laboratory, Instituto Butantan, São Paulo 05503-900, SP, Brazil.
Nicole Caroline Mambelli-LisboaGenetics Laboratory, Instituto Butantan, São Paulo 05503-900, SP, Brazil.
Leandro Hideki YnoueAzidus Brasil, Valinhos 13271-130, SP, Brazil.
Rodrigo Pinheiro AraldiCellavita Pesquisas Científicas Ltda., Valinhos 13271-650, SP, Brazil.ORCID 0000-0001-8288-2577
Joyce Macedo da SilvaAzidus Brasil, Valinhos 13271-130, SP, Brazil.
Eduardo PaganiAzidus Brasil, Valinhos 13271-130, SP, Brazil.
Monica Santoro HaddadHospital das Clínicas, Faculdade de Medicina, Universidade Estadual de Campinas (UNICAMP), Campinas 13083-872, SP, Brazil.
Irina KerkisGenetics Laboratory, Instituto Butantan, São Paulo 05503-900, SP, Brazil.
Instituto Butantan · BRUniversidade Estadual de Campinas (UNICAMP) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Huntington's disease (HD) is a neurodegenerative inherited genetic disorder, which leads to the onset of motor, neuropsychiatric and cognitive disturbances. HD is characterized by the loss of gamma-aminobutyric acid (GABA)ergic medium spiny neurons (MSNs). To date, there is no treatment for HD. Mesenchymal stem cells (MSCs) provide a substantial therapeutic opportunity for the HD treatment. Herein, we investigated the therapeutic potential of human immature dental pulp stem cells (hIDPSC), a special type of MSC originated from the neural crest, for HD treatment. Two different doses of hIDPSC were intravenously administrated in a subacute 3-nitropropionic acid (3NP)-induced rat model. We demonstrated hIDPSC homing in the striatum, cortex and subventricular zone using specific markers for human cells. Thirty days after hIDPSC administration, the cells found in the brain are still express hallmarks of undifferentiated MSC. Immunohistochemistry quantities analysis revealed a significant increase in the number of BDNF, DARPP32 and D2R positive stained cells in the striatum and cortex in the groups that received hIDPSC. The differences were more expressive in animals that received only one administration of hIDPSC. Altogether, these data suggest that the intravenous administration of hIDPSCs can restore the BDNF, DARPP32 and D2R expression, promoting neuroprotection and neurogenesis.

Indexed as

Brain-Derived Neurotrophic FactorDopamine and cAMP-Regulated Phosphoprotein 32Huntington DiseaseStem CellsStem Cell TransplantationAnimalsDental PulpDisease Models, AnimalHumansInfusions, IntravenousRatsBdnf protein, ratBrain-Derived Neurotrophic FactorDopamine and cAMP-Regulated Phosphoprotein 32Ppp1r1b protein, rat3-nitropropionic acid (3-NP)brain-derived neurotrophic factor (BDNF)human immature dental pulp stem cells (hIDPSC)huntington disease (HD)neurotrophic influences

Identifiers

PMID35626701
PMCPMC9139280
OpenAlexW4280607468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.